## ABSTRACT OF THE DISCLOSURE

The present invention relates to a class of compounds represented by the Formula 1.

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively inhibiting or antagonizing the  $\alpha_V \beta_3$  and/or the  $\alpha_V \beta_5$  integrin.

Scheme

1. Pd(OAc)<sub>2</sub> (Bu)<sub>4</sub>NCl, K<sub>2</sub>CO<sub>3</sub> DMF, 65 °C, 2.5 h 2. AgCO<sub>3</sub>, Celite Toluene, 80 °C 1h

$$1a,R = H$$
  
 $1b,R = F$ 

2a, R = H2b, R = F

Scheme

1.K<sub>2</sub>CO<sub>3</sub>, 18·C·6 DMF, 75 °C, 16 h 2. HCl/Dioxane, EiOH 70 °C 1 h MeO S OEt 4a, R = H 4b, R = F

2a, R = H2b R = F

2

1. Oxone, EtOH/Water RT, 3 h 2. BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub> RT, 1 h PPh<sub>3</sub>, DIAD THF, DMF

2.Cyclohexene/Pd/C (10%), EtOH Reflux 3. LiOH. 70 °C, 45 min